View in EDS

Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration.

Saved in:
Bibliographic Details
Title: Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration.
Authors: Zhao G; Cancer Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana. Zhao_Genshi@Lilly.com., Green CF; Toxicology, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Hui YH; Drug Disposition, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Prieto L; Discovery Chemistry Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Shepard R; Cancer Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Dong S; Cancer Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Wang T; Cancer Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Tan B; Toxicology, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Gong X; Cancer Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Kays L; Cancer Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Johnson RL; Toxicology, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Wu W; Cancer Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Bhattachar S; Product Design and Developability, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Del Prado M; Discovery Chemistry Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Gillig JR; Discovery Chemistry Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Fernandez MC; Discovery Chemistry Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Roth KD; Discovery Chemistry Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Buchanan S; Cancer Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Kuo MS; Discovery Chemistry Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Geeganage S; Cancer Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Burkholder TP; Discovery Chemistry Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.
Source: Molecular cancer therapeutics [Mol Cancer Ther] 2017 Dec; Vol. 16 (12), pp. 2677-2688. Date of Electronic Publication: 2017 Oct 20.
Publication Type: Journal Article
Journal Info: Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 29054982
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Zhao+G%22">Zhao G</searchLink>; Cancer Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana. Zhao_Genshi@Lilly.com.<br /><searchLink fieldCode="AU" term="%22Green+CF%22">Green CF</searchLink>; Toxicology, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.<br /><searchLink fieldCode="AU" term="%22Hui+YH%22">Hui YH</searchLink>; Drug Disposition, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.<br /><searchLink fieldCode="AU" term="%22Prieto+L%22">Prieto L</searchLink>; Discovery Chemistry Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.<br /><searchLink fieldCode="AU" term="%22Shepard+R%22">Shepard R</searchLink>; Cancer Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.<br /><searchLink fieldCode="AU" term="%22Dong+S%22">Dong S</searchLink>; Cancer Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.<br /><searchLink fieldCode="AU" term="%22Wang+T%22">Wang T</searchLink>; Cancer Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.<br /><searchLink fieldCode="AU" term="%22Tan+B%22">Tan B</searchLink>; Toxicology, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.<br /><searchLink fieldCode="AU" term="%22Gong+X%22">Gong X</searchLink>; Cancer Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.<br /><searchLink fieldCode="AU" term="%22Kays+L%22">Kays L</searchLink>; Cancer Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.<br /><searchLink fieldCode="AU" term="%22Johnson+RL%22">Johnson RL</searchLink>; Toxicology, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.<br /><searchLink fieldCode="AU" term="%22Wu+W%22">Wu W</searchLink>; Cancer Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.<br /><searchLink fieldCode="AU" term="%22Bhattachar+S%22">Bhattachar S</searchLink>; Product Design and Developability, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.<br /><searchLink fieldCode="AU" term="%22Del+Prado+M%22">Del Prado M</searchLink>; Discovery Chemistry Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.<br /><searchLink fieldCode="AU" term="%22Gillig+JR%22">Gillig JR</searchLink>; Discovery Chemistry Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.<br /><searchLink fieldCode="AU" term="%22Fernandez+MC%22">Fernandez MC</searchLink>; Discovery Chemistry Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.<br /><searchLink fieldCode="AU" term="%22Roth+KD%22">Roth KD</searchLink>; Discovery Chemistry Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.<br /><searchLink fieldCode="AU" term="%22Buchanan+S%22">Buchanan S</searchLink>; Cancer Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.<br /><searchLink fieldCode="AU" term="%22Kuo+MS%22">Kuo MS</searchLink>; Discovery Chemistry Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.<br /><searchLink fieldCode="AU" term="%22Geeganage+S%22">Geeganage S</searchLink>; Cancer Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.<br /><searchLink fieldCode="AU" term="%22Burkholder+TP%22">Burkholder TP</searchLink>; Discovery Chemistry Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101132535%22">Molecular cancer therapeutics</searchLink> [Mol Cancer Ther] 2017 Dec; Vol. 16 (12), pp. 2677-2688. <i>Date of Electronic Publication: </i>2017 Oct 20.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Association+for+Cancer+Research%2C+Inc%22">American Association for Cancer Research, Inc </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101132535 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1538-8514 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2215357163%22">15357163 </searchLink><i>NLM ISO Abbreviation: </i>Mol Cancer Ther <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=29054982
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1158/1535-7163.MCT-16-0674
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 2677
    Titles:
      – TitleFull: Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Zhao G
      – PersonEntity:
          Name:
            NameFull: Green CF
      – PersonEntity:
          Name:
            NameFull: Hui YH
      – PersonEntity:
          Name:
            NameFull: Prieto L
      – PersonEntity:
          Name:
            NameFull: Shepard R
      – PersonEntity:
          Name:
            NameFull: Dong S
      – PersonEntity:
          Name:
            NameFull: Wang T
      – PersonEntity:
          Name:
            NameFull: Tan B
      – PersonEntity:
          Name:
            NameFull: Gong X
      – PersonEntity:
          Name:
            NameFull: Kays L
      – PersonEntity:
          Name:
            NameFull: Johnson RL
      – PersonEntity:
          Name:
            NameFull: Wu W
      – PersonEntity:
          Name:
            NameFull: Bhattachar S
      – PersonEntity:
          Name:
            NameFull: Del Prado M
      – PersonEntity:
          Name:
            NameFull: Gillig JR
      – PersonEntity:
          Name:
            NameFull: Fernandez MC
      – PersonEntity:
          Name:
            NameFull: Roth KD
      – PersonEntity:
          Name:
            NameFull: Buchanan S
      – PersonEntity:
          Name:
            NameFull: Kuo MS
      – PersonEntity:
          Name:
            NameFull: Geeganage S
      – PersonEntity:
          Name:
            NameFull: Burkholder TP
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: 2017 Dec
              Type: published
              Y: 2017
          Identifiers:
            – Type: issn-electronic
              Value: 1538-8514
          Numbering:
            – Type: volume
              Value: 16
            – Type: issue
              Value: 12
          Titles:
            – TitleFull: Molecular cancer therapeutics
              Type: main
ResultId 1